Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Total Current Liabilities (2021 - 2025)

Roivant Sciences (ROIV) has disclosed Total Current Liabilities for 5 consecutive years, with $152.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities fell 53.9% year-over-year to $152.0 million, compared with a TTM value of $152.0 million through Dec 2025, down 53.9%, and an annual FY2025 reading of $149.4 million, down 43.99% over the prior year.
  • Total Current Liabilities was $152.0 million for Q4 2025 at Roivant Sciences, up from $133.9 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $556.2 million in Q3 2024 and bottomed at $113.9 million in Q2 2025.
  • Average Total Current Liabilities over 5 years is $244.6 million, with a median of $237.5 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities soared 109.47% in 2024, then plummeted 75.94% in 2025.
  • Year by year, Total Current Liabilities stood at $160.7 million in 2021, then soared by 51.98% to $244.3 million in 2022, then rose by 27.36% to $311.1 million in 2023, then increased by 5.96% to $329.6 million in 2024, then plummeted by 53.9% to $152.0 million in 2025.
  • Business Quant data shows Total Current Liabilities for ROIV at $152.0 million in Q4 2025, $133.9 million in Q3 2025, and $113.9 million in Q2 2025.